In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The New Oral MS Drugs: The Challenges in Dislodging Biologics

Executive Summary

Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.

Related Content

EU Regulators Reject Merck KGaA's Oral MS Drug Cladribine
Biogen Idec Taps Exelixis' Scangos To Be New CEO
Biogen Idec Taps Exelixis' Scangos To Be New CEO
EU Regulators Up The Number of Tysabri-Related PML Cases, Re-Open a Safety Review
Novartis Finds FREEDOM From Fingolimod Concerns In Second Phase III, Limits Dose To Play It Safe
MannKind's Uphill Climb to Partner Inhaled Insulin
Teva's Copaxone Continues To Widen MS Market Lead In U.S.
Insulin Delivery: Still Waiting to Exhale
Antegren: Shaking Up the MS Market?
Antegren: Shaking Up the MS Market?


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts